Delcath to start phase III cancer therapy trial
This article was originally published in Clinica
Executive Summary
The US FDA has given chemotherapy delivery device maker Delcath Systems the all-clear to begin a phase III trial of its technology for treating metastatic melanoma in the liver with melphalan.